330791-69-0Relevant academic research and scientific papers
Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases
Wang, Gary T.,Mantei, Robert A.,Hubbard, Robert D.,Wilsbacher, Julie L.,Zhang, Qian,Tucker, Lora,Hu, Xiaoming,Kovar, Peter,Johnson, Eric F.,Osterling, Donald J.,Bouska, Jennifer,Wang, Jieyi,Davidsen, Steven K.,Bell, Randy L.,Sheppard, George S.
scheme or table, p. 6067 - 6071 (2010/11/18)
This Letter describes the lead discovery, optimization, and biological characterization of a series of substituted 4-amino-1H-pyrazolo[3,4-d] pyrimidines as potent inhibitors of IGF1R, EGFR, and ErbB2. The leading compound 11 showed an IGF1R IC50 of 12 nM, an EGFR (L858R) IC50 of 31 nM, and an ErbB2 IC50 of 11 nM, potent activity in cellular functional and anti-proliferation assays, as well as activity in an in vivo pharmacodynamic assay.
Pyrazolopyrimidines as therapeutic agents
-
, (2008/06/13)
The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.
Pyrazolopyrimidines as therapeutic agents
-
, (2008/06/13)
The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R2, and R3 are defined as described herein.
